David Ho, Virtual COVID-19 Symposium: February 17, 2021 скачать в хорошем качестве

David Ho, Virtual COVID-19 Symposium: February 17, 2021

David Ho, MD, Founding Scientific Director and Chief Executive Officer, Aaron Diamond AIDS Research Center, Helen Wu Professor of Medicine, Columbia University, Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization The B.1.1.7 and B.1.351 SARS-CoV-2 variants have garnered wide attention due to their rapid proliferation and increased virulence in the UK and South Africa, respectively. In in vitro selection experiments putting monoclonal antibody pressure on SARS-CoV-2, Dr. Ho’s group observed sequential mutations that were strikingly similar to the B.1.1.7 and B.1.351 variants, suggesting that these mutations will become a common feature of SARS-CoV-2 evolution. By testing a battery of candidate antibodies, convalescent plasma, as well as serum from vaccine recipients against these variants, Dr. Ho illustrates challenges likely to come in the response to the quickly-evolving SARS-CoV-2 virus. In particular, the B.1.351 (South Africa) variant appeared to confer dramatically greater resistance to neutralization by leading clinical antibody treatments, convalescent sera, and vaccinee sera (from both Pfizer and Moderna vaccine recipients). Finally, Dr. Ho and collaborators are monitoring SARS-CoV-2 samples in the New York metropolitan area, and identify a novel variant (B.1.526) with several homologous mutations that similarly confer significant resistance to vaccine-stimulated antibodies and extant monoclonal antibody treatments.